The partnership between the firms will allow women, regardless of income and insurance coverage, to access this new and effective contraceptive option. Liletta is a small, flexible plastic
The agency also granted priority review for this BLA and has given the Prescription Drug User Fee Act (PDUFA) goal date of 22 June 2015 for a decision.
Standard chemotherapy includes paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan for patients who cannot receive platinum therapy. Cervical cancer is most commonly diagnosed in women aged between
If Zykadia receives approval in the European Union (EU), it will be the first treatment option to address an unmet medical need for these patients. Zykadia is an
To be launched in Germany, Italy, the UK, Netherlands, Belgium and Luxembourg, Remsima is authorised for the treatment of patients with Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing
The company said that TRPH 011 binds and neutralizes VEGFR-2/KDR and TIE 2 receptors simultaneously, resulting in sustained inhibition of tumor growth and angiogenesis. Angiogenesis is the formation
The proposed plan follows a pre-investigational new drug (IND) submission feedback from the US Food and Drug Administration (FDA), which provided guidance on the clinical plan, manufacturing approach,
The trial evaluated the safety, tolerability and pharmacokinetics of OBE001 and betamethasone, a corticosteroid, when co-administered to healthy non-pregnant women. Betamethasone is administered to prevent respiratory distress syndrome
The drug is being developed for the treatment of patients with relapsed/refractory and frontline intermediate or high-risk AML and is currently been evaluated in multiple Phase II clinical
At present, there is no approved antidote to treat these patients and andexanet alfa has the potential to become the first approved universal antidote for Factor Xa inhibitors
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.